Dual GLP-1 and glucagon receptor mechanism

Two receptors, two organs, one weekly signal

Survodutide works by switching on two receptors whose classical jobs sit in different places. The GLP-1 receptor carries appetite, gastric emptying and glucose-dependent insulin; glucagon's classical actions are hepatic, and the preclinical work reads that arm out with liver markers. This unit maps where each arm acts, then builds the biology underneath: why the insulin boost is glucose-dependent, why the glucagon signal is kept restrained by design, and how the body reveals that both arms are engaged.

This is the mechanistic core the trial units later test against real outcomes. Get the two-receptor picture clear here, and the obesity, MASH, and safety data all read as consequences of it.